Some amounts in this presentation may not add up due to rounding. All percentages have been calculated using unrounded amounts. − Significant foreign exchange headwinds on revenues: − Debt reduction continues; net debt reduced to $18.4 billion − Europerevenues up 9% in local currency, reflecting higher demand and successful new product launches, including generic Eliquis® * Compared to Q4 2021 ** Compared to FY 2021 | 5 | 54,832 0 10,000 20,000 30,000 40,000 50,000 60,000 Source: IQVIA US NPA Audit Source: ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other ju ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2022 Earnings Conference Call February 8, 2023 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Head of Investor Relations Richard Francis - Chief Executive Officer Eli Kalif - Executive Vice President and Chief Financial Officer Sven Dethlefs - Executive Vice President, North America Commercial Conference Call Participants Umer Raffat - Evercore ISI Gary Nachman - BMO Capital Markets Glen Santangelo - Jefferies Jason Gerberry - Bank ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) 41st Annual J.P. Morgan Healthcare Conference January 11, 2023 1:30 PM ET Company Participants Eli Kalif - Executive Vice President and Chief Financial Officer Richard Francis - President and CEO Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Teva this morning. From the company, we have the company's recently appointed CEO, Richard Francis; as well ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Head of Investor Relations Kare Schultz - President and Chief Executive Officer Eli Kalif - Executive Vice President and Chief Financial Officer Sven Dethlefs - Executive Vice President, North America Commercial Conference Call Participants Elliot Wilbur - Raymond James Glen Santangelo - Jefferies Umer Raffat - Evercore Jason Gerberry - Bank o ...

| --- | --- | |----------------------------------------------------------------|-------| | | | | | | | Teva Pharmaceutical Industries Ltd. Third Quarter 2022 Results | | | November 3, 2022 | | Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q2 2022 Earnings Conference Call July 27, 2022 8:00 AM ET Company Participants Ran Meir – Senior Vice President, Head of Investor Relations Kare Schultz – Chief Executive Officer Eli Kalif – Chief Financial Officer Sven Dethlefs – Executive Vice President, North America Commercial Conference Call Participants Balaji Prasad – Barclays Nathan Rich – Goldman Sachs Umer Raffat – Evercore Jason Gerberry – Bank of America Ashwani Verma – UBS Elliot Wilbur – Raymo ...

| --- | --- | |-----------------------------|-------| | | | | Second Quarter 2022 Results | | | July 27, 2022 | | Agenda 1 Opioid litigation updates 2 Second quarter 2022 results 3 Strategy update and 2027 long-term financial targets 4 Q&A teva Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Israel Not ...